首页 > 最新文献

Surgical Oncology Insight最新文献

英文 中文
Pelvic Floor Physical Therapy Prehabilitation (PrePFPT) for the prevention of low anterior resection syndrome 预防低位前切除综合征的盆底物理疗法预康复(PrePFPT)
Pub Date : 2024-09-07 DOI: 10.1016/j.soi.2024.100097
Nathan A. Coppersmith , Kurt S. Schultz , Andrew C. Esposito , Kimberly Reinhart , Emily Ray , Ira L. Leeds , Haddon J. Pantel , Vikram B. Reddy , Walter E. Longo , Anne K. Mongiu

Low Anterior Resection Syndrome (LARS) is a syndrome of lifestyle-limiting defecatory dysfunction diagnosed after the treatment of rectal cancer that can afflict 41 % of patients one year after surgery. Currently, the treatment of LARS is reactionary to the development of symptoms, and post-treatment pelvic floor physical therapy (PFPT) is one form of treatment utilized to mitigate the symptoms of LARS and improve patient quality of life. Prehabilitation is the physical and/or lifestyle preparation that improves recovery following surgery. For rectal cancer patients, general prehabilitation while undergoing neoadjuvant chemoradiotherapy is safe and feasible. However, no studies have examined whether pelvic floor physical therapy prehabilitation, which we term “PrePFPT,” could mitigate the development of LARS. In this commentary, we argue that PrePFPT should become an active area of research in rectal cancer to improve functional and quality of life outcomes. We highlight two proposed international trials, which will evaluate pre- and postoperative PFPT as a strategy to reduce the incidence of LARS. We conclude with our own proposed PrePFPT study design.

低位前切除综合征(LARS)是一种在直肠癌治疗后被诊断出的限制生活方式的排便功能障碍综合征,41%的患者在术后一年会出现这种症状。目前,治疗 LARS 的方法是根据症状的发展作出反应,治疗后盆底物理治疗 (PFPT) 是减轻 LARS 症状和提高患者生活质量的一种治疗方法。术前康复是指在身体和/或生活方式上做好准备,以改善术后恢复。对于直肠癌患者来说,在接受新辅助放化疗的同时进行一般康复训练是安全可行的。然而,还没有研究探讨盆底物理治疗前康复(我们称之为 "PrePFPT")是否能减轻 LARS 的发生。在这篇评论中,我们认为盆底物理治疗前康复训练应成为直肠癌的一个积极研究领域,以改善功能和生活质量。我们重点介绍了两项拟议的国际试验,这两项试验将评估术前和术后 PFPT 作为降低 LARS 发生率的策略。最后,我们提出了自己的 PrePFPT 研究设计方案。
{"title":"Pelvic Floor Physical Therapy Prehabilitation (PrePFPT) for the prevention of low anterior resection syndrome","authors":"Nathan A. Coppersmith ,&nbsp;Kurt S. Schultz ,&nbsp;Andrew C. Esposito ,&nbsp;Kimberly Reinhart ,&nbsp;Emily Ray ,&nbsp;Ira L. Leeds ,&nbsp;Haddon J. Pantel ,&nbsp;Vikram B. Reddy ,&nbsp;Walter E. Longo ,&nbsp;Anne K. Mongiu","doi":"10.1016/j.soi.2024.100097","DOIUrl":"10.1016/j.soi.2024.100097","url":null,"abstract":"<div><p>Low Anterior Resection Syndrome (LARS) is a syndrome of lifestyle-limiting defecatory dysfunction diagnosed after the treatment of rectal cancer that can afflict 41 % of patients one year after surgery. Currently, the treatment of LARS is reactionary to the development of symptoms, and post-treatment pelvic floor physical therapy (PFPT) is one form of treatment utilized to mitigate the symptoms of LARS and improve patient quality of life. Prehabilitation is the physical and/or lifestyle preparation that improves recovery following surgery. For rectal cancer patients, general prehabilitation while undergoing neoadjuvant chemoradiotherapy is safe and feasible. However, no studies have examined whether pelvic floor physical therapy prehabilitation, which we term “PrePFPT,” could mitigate the development of LARS. In this commentary, we argue that PrePFPT should become an active area of research in rectal cancer to improve functional and quality of life outcomes. We highlight two proposed international trials, which will evaluate pre- and postoperative PFPT as a strategy to reduce the incidence of LARS. We conclude with our own proposed PrePFPT study design.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100097"},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001063/pdfft?md5=1503e54387f16fc32d75bc1d4ded9c65&pid=1-s2.0-S2950247024001063-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pepsinogen and Helicobacter pylori: Serum biomarkers for gastric cancer risk in a diverse United States population 胃蛋白酶原和幽门螺旋杆菌:美国不同人群胃癌风险的血清生物标志物
Pub Date : 2024-09-01 DOI: 10.1016/j.soi.2024.100086
Haejin In , Alexandra Adams , Sammy Ho , Srawani Sarkar , Fei Wang , Aaron Oh , Dong Jun Yun , Atish Gandhi , Shengguo Li , Hao Liu , Douglas R. Morgan , Julie Yang

Background

Serum Pepsinogen (PG) and Helicobacter pylori (Hp) have potential as biomarkers to identify persons at high risk for gastric cancer (GC) in low incidence populations. We explored the use of these biomarkers in a diverse US population.

Methods

Single institution study using serum samples from 32 newly diagnosed GC (before treatment) and 60 non-cancer participants. ELISA-based PG-I, PG-II, Hp IgG, and Hp virulence seromarker (CagA, VacA) tests were conducted to examine differences between GC and non-GC participants.

Results

Median age was 58 (IQR 48–68); 56 % were females; 30.1 % were white, 14.8 % black, 28.7 % Hispanic, 6.1 % Asian and 18.2 % other/unknown race/ethnicity. Median values of Hp (47.9 vs 12.6 U/mL, p = 0.003) and pepsinogen ratio (PGR=PGI/PGII) (4.0 vs 7.5, p = 0.003) differed between GC and non-GC. Performance of pepsinogen tests using “standard” cut-offs (PGI ≤ 70 ng/mL and PGR ≤ 3) were highly specific (91.7 %), but not sensitive (34.4 %), while Hp IgG test using “standard” cut-off (≥ 30 U/mL) was sensitive (78.8 %), but less specific (41.2 %). Optimized cut-off values identified in our population using Youden’s Index were PGR ≤ 5.2 and Hp ≥ 17.5 U/mL. Using a combination of these values resulted in a significant increase in test sensitivity (87.9 %) with lower specificity (50.8 %).

Conclusion

The combination of pepsinogens and Hp show promise as biomarkers of GC risk in a racially and ethnically diverse US population. Optimal biomarker cut-off points for US populations may differ from those established in East Asia. By adjusting cut-offs there is potential to design GC risk stratification tools tailored specifically for the diverse population within the US.

背景血清胃蛋白酶原 (PG) 和幽门螺旋杆菌 (Hp) 有可能作为生物标记物来识别低发病率人群中的胃癌 (GC) 高危人群。我们探讨了这些生物标记物在美国不同人群中的使用情况。方法单个机构研究使用 32 名新诊断为 GC(治疗前)和 60 名非癌症参与者的血清样本。结果平均年龄为 58 岁(IQR 48-68);56% 为女性;30.1% 为白人,14.8% 为黑人,28.7% 为西班牙裔,6.1% 为亚裔,18.2% 为其他/未知种族/族裔。胃蛋白酶中位值(47.9 vs 12.6 U/mL,P = 0.003)和胃蛋白酶原比率(PGR=PGI/PGII)(4.0 vs 7.5,P = 0.003)在胃癌和非胃癌之间存在差异。使用 "标准 "临界值(PGI ≤ 70 ng/mL,PGR ≤ 3)进行胃蛋白酶原检测的特异性很高(91.7%),但灵敏度不高(34.4%),而使用 "标准 "临界值(≥ 30 U/mL)进行肝IgG检测的灵敏度较高(78.8%),但特异性较低(41.2%)。根据尤登指数(Youden's Index),在我国人群中确定的最佳临界值为 PGR ≤ 5.2 和 Hp ≥ 17.5 U/mL。结论胃蛋白酶原和 Hp 的组合有望成为美国种族和民族多样化人群中 GC 风险的生物标志物。美国人群的最佳生物标志物截断点可能与东亚地区的截断点不同。通过调整临界点,有可能设计出专门针对美国不同人群的 GC 风险分层工具。
{"title":"Pepsinogen and Helicobacter pylori: Serum biomarkers for gastric cancer risk in a diverse United States population","authors":"Haejin In ,&nbsp;Alexandra Adams ,&nbsp;Sammy Ho ,&nbsp;Srawani Sarkar ,&nbsp;Fei Wang ,&nbsp;Aaron Oh ,&nbsp;Dong Jun Yun ,&nbsp;Atish Gandhi ,&nbsp;Shengguo Li ,&nbsp;Hao Liu ,&nbsp;Douglas R. Morgan ,&nbsp;Julie Yang","doi":"10.1016/j.soi.2024.100086","DOIUrl":"10.1016/j.soi.2024.100086","url":null,"abstract":"<div><h3>Background</h3><p>Serum Pepsinogen (PG) and <em>Helicobacter pylori</em> (Hp) have potential as biomarkers to identify persons at high risk for gastric cancer (GC) in low incidence populations. We explored the use of these biomarkers in a diverse US population.</p></div><div><h3>Methods</h3><p>Single institution study using serum samples from 32 newly diagnosed GC (before treatment) and 60 non-cancer participants. ELISA-based PG-I, PG-II, <em>Hp</em> IgG, and <em>Hp</em> virulence seromarker (CagA, VacA) tests were conducted to examine differences between GC and non-GC participants.</p></div><div><h3>Results</h3><p>Median age was 58 (IQR 48–68); 56 % were females; 30.1 % were white, 14.8 % black, 28.7 % Hispanic, 6.1 % Asian and 18.2 % other/unknown race/ethnicity. Median values of Hp (47.9 vs 12.6 U/mL, p = 0.003) and pepsinogen ratio (PGR=PGI/PGII) (4.0 vs 7.5, p = 0.003) differed between GC and non-GC. Performance of pepsinogen tests using “standard” cut-offs (PGI ≤ 70 ng/mL and PGR ≤ 3) were highly specific (91.7 %), but not sensitive (34.4 %), while Hp IgG test using “standard” cut-off (≥ 30 U/mL) was sensitive (78.8 %), but less specific (41.2 %). Optimized cut-off values identified in our population using Youden’s Index were PGR ≤ 5.2 and Hp ≥ 17.5 U/mL. Using a combination of these values resulted in a significant increase in test sensitivity (87.9 %) with lower specificity (50.8 %).</p></div><div><h3>Conclusion</h3><p>The combination of pepsinogens and Hp show promise as biomarkers of GC risk in a racially and ethnically diverse US population. Optimal biomarker cut-off points for US populations may differ from those established in East Asia. By adjusting cut-offs there is potential to design GC risk stratification tools tailored specifically for the diverse population within the US.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100086"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000951/pdfft?md5=e7731a8c74fbbf81ed7ca9176c736bcd&pid=1-s2.0-S2950247024000951-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How reliable are post-mastectomy breast reconstruction videos on YouTube? YouTube 上的乳房切除术后乳房再造视频有多可靠?
Pub Date : 2024-08-30 DOI: 10.1016/j.soi.2024.100094
Nina Morena , Libby Ben-Zvi , Victoria Hayman , Mary Hou , Andrew Gorgy , Diana Nguyen , Carrie A. Rentschler , Ari N. Meguerditchian

Background

Social media platforms are a significant source of information for young women with breast cancer (YWBC) undergoing post-mastectomy breast reconstruction (PMBR). The emphasis on visual storytelling and building community in online spaces renders YouTube to be a common platform for discussions of BR. This study aims to assess the quality of YouTube videos about PMBR, identify themes related to the PMBR experience, and quantify suggestions of BR as an option PM.

Methods

YouTube was searched incognito with terms “young women breast cancer reconstruction” in 08/2022, in order from most to least viewed. Title, upload date, length, poster identity, number of likes and comments were collected. The Patient Education Materials Assessment Tool for audiovisual materials (PEMAT A/V) was used to evaluate understandability and actionability. DISCERN assessed quality and reliability. Presence of sponsorship, intended audience, patient and healthcare professional narratives, and suggestions of PMBR were collected. Reviewers noted whether PMBR was shown and how. Themes were collected inductively and deductively for thematic analysis.

Results

193 videos were identified. Mean video length was 14.6 min (SD 20.0 min). 87.1 % included sponsorships. 95.9 % of videos were posted by an organization. 60.6 % were information-based; 45.6 % experience-based. Mean PEMAT scores for understandability and actionability were 71.3 % (SD 13.4) and 35.7 % (SD 41.8), respectively. Mean DISCERN was 2.6/5 (SD 1.2). Patient narrative was present in 52.6 % and healthcare professionals’ in 68.4 %. PMBR was visually presented 22.8 % of the time. 13.5 % of videos explicitly recommended PMBR. 2.6 % explicitly discouraged it. Patients (77.7 %) represented the majority of the intended audience. Most common deductively identified themes included treatment (87.1 %), family relationship (17.1 %), motherhood (15.5 %), fertility (11.9 %). Inductively identified subthemes included differentiating between various options for PMBR surgery, BRCA genetic testing, psychosocial effects of breast cancer and PMBR, and recovery from surgery.

Conclusion

YouTube is a platform wherein various PMBR options are widely discussed and explained. PMBR videos are highly understandable but have moderate levels of actionability, quality, and reliability. Videos are highly sponsored, demonstrating significant institutional bias. Themes are overwhelmingly treatment and surgery-based. Personal themes were present but not dominant.

背景社交媒体平台是乳腺癌年轻女性患者进行乳房切除术后重建(PMBR)的重要信息来源。YouTube强调在网络空间中讲述视觉故事和建立社区,因此成为讨论乳房再造的常见平台。本研究旨在评估 YouTube 上有关 PMBR 的视频质量,确定与 PMBR 体验相关的主题,并量化将 BR 作为 PM 选项的建议。收集了标题、上传日期、长度、海报身份、点赞数和评论数。患者教育材料评估工具(PEMAT A/V)用于评估视听材料的可理解性和可操作性。DISCERN 评估质量和可靠性。收集了赞助商、目标受众、患者和医护人员的叙述以及对 PMBR 的建议。审稿人注意到是否显示了 PMBR 以及如何显示。通过归纳和演绎收集主题,进行主题分析。平均视频长度为 14.6 分钟(标准差为 20.0 分钟)。87.1%的视频包含赞助。95.9%的视频由某个组织发布。60.6%的视频以信息为基础;45.6%的视频以体验为基础。可理解性和可操作性的 PEMAT 平均得分分别为 71.3 %(标准差 13.4)和 35.7 %(标准差 41.8)。DISCERN 的平均值为 2.6/5(标准差 1.2)。患者叙述占 52.6%,医护人员叙述占 68.4%。22.8%的视频以直观的方式展示了 PMBR。13.5% 的视频明确推荐 PMBR。2.6%的视频明确表示不推荐。患者(77.7%)占目标受众的大多数。最常见的演绎主题包括治疗(87.1%)、家庭关系(17.1%)、母性(15.5%)和生育(11.9%)。归纳出的次主题包括区分各种 PMBR 手术选择、BRCA 基因检测、乳腺癌和 PMBR 的社会心理影响以及术后恢复。PMBR 视频的可理解性很高,但可操作性、质量和可靠性处于中等水平。视频得到了大量赞助,显示出明显的机构偏见。主题绝大多数以治疗和手术为主。个人主题存在,但不占主导地位。
{"title":"How reliable are post-mastectomy breast reconstruction videos on YouTube?","authors":"Nina Morena ,&nbsp;Libby Ben-Zvi ,&nbsp;Victoria Hayman ,&nbsp;Mary Hou ,&nbsp;Andrew Gorgy ,&nbsp;Diana Nguyen ,&nbsp;Carrie A. Rentschler ,&nbsp;Ari N. Meguerditchian","doi":"10.1016/j.soi.2024.100094","DOIUrl":"10.1016/j.soi.2024.100094","url":null,"abstract":"<div><h3>Background</h3><p>Social media platforms are a significant source of information for young women with breast cancer (YWBC) undergoing post-mastectomy breast reconstruction (PMBR). The emphasis on visual storytelling and building community in online spaces renders YouTube to be a common platform for discussions of BR. This study aims to assess the quality of YouTube videos about PMBR, identify themes related to the PMBR experience, and quantify suggestions of BR as an option PM.</p></div><div><h3>Methods</h3><p>YouTube was searched incognito with terms “young women breast cancer reconstruction” in 08/2022, in order from most to least viewed. Title, upload date, length, poster identity, number of likes and comments were collected. The Patient Education Materials Assessment Tool for audiovisual materials (PEMAT A/V) was used to evaluate understandability and actionability. DISCERN assessed quality and reliability. Presence of sponsorship, intended audience, patient and healthcare professional narratives, and suggestions of PMBR were collected. Reviewers noted whether PMBR was shown and how. Themes were collected inductively and deductively for thematic analysis.</p></div><div><h3>Results</h3><p>193 videos were identified. Mean video length was 14.6 min (SD 20.0 min). 87.1 % included sponsorships. 95.9 % of videos were posted by an organization. 60.6 % were information-based; 45.6 % experience-based. Mean PEMAT scores for understandability and actionability were 71.3 % (SD 13.4) and 35.7 % (SD 41.8), respectively. Mean DISCERN was 2.6/5 (SD 1.2). Patient narrative was present in 52.6 % and healthcare professionals’ in 68.4 %. PMBR was visually presented 22.8 % of the time. 13.5 % of videos explicitly recommended PMBR. 2.6 % explicitly discouraged it. Patients (77.7 %) represented the majority of the intended audience. Most common deductively identified themes included treatment (87.1 %), family relationship (17.1 %), motherhood (15.5 %), fertility (11.9 %). Inductively identified subthemes included differentiating between various options for PMBR surgery, BRCA genetic testing, psychosocial effects of breast cancer and PMBR, and recovery from surgery.</p></div><div><h3>Conclusion</h3><p>YouTube is a platform wherein various PMBR options are widely discussed and explained. PMBR videos are highly understandable but have moderate levels of actionability, quality, and reliability. Videos are highly sponsored, demonstrating significant institutional bias. Themes are overwhelmingly treatment and surgery-based. Personal themes were present but not dominant.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100094"},"PeriodicalIF":0.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001038/pdfft?md5=62a065ee51c87e594bdcc2000e6131dc&pid=1-s2.0-S2950247024001038-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical management of peritoneal metastases from appendix and colon cancer in patients with inflammatory bowel disease 炎症性肠病患者阑尾和结肠癌腹膜转移的手术治疗
Pub Date : 2024-08-30 DOI: 10.1016/j.soi.2024.100092
Vladislav Kovalik, Mary Caitlin King, Sergei Iugai, Luis Felipe Falla-Zuniga, Carol Nieroda, Armando Sardi, Vadim Gushchin

Background

Inflammatory bowel disease (IBD) may compromise outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal metastases (PM) from appendix/colon cancer. We evaluated CRS/HIPEC outcomes in patients with concurrent IBD.

Methods

A matched cohort study using a prospective institutional CRS/HIPEC database (1998–2023) included appendix/colon cancer patients with PM. We matched IBD patients to IBD-free controls in a 1:5 ratio with nearest-neighbor propensity score for sex, age, and peritoneal cancer index (PCI), and exact matching for prior CRS/HIPEC and primary tumor. Perioperative variables, including Clavien-Dindo 90-day complications, were compared. Kaplan-Meier overall (OS) and progression-free survival (PFS) were compared using stratified Cox regression.

Results

Of 605 CRS/HIPECs for appendix/colon cancer, 14 (2.3%) had concurrent Crohn’s disease (n = 6) or ulcerative colitis (n = 8). Seventy IBD-free controls were matched. Nine (64.7%) IBD patients had an appendix primary. Complete cytoreduction (CC-0/1) was achieved in 10 (71.4%) IBD and 57 (81.4%) IBD-free patients (p = 0.468). IBD vs IBD-free patients tended to have more grade-III/IV complications (35.7% [n = 5] vs 15.7% [n = 11], p = 0.082) and had a higher rate of severe nausea/vomiting (35.7% vs 4.3 %, p < 0.001) and diarrhea (28.6% vs 8.6%, p = 0.035). Rates of anastomotic leak (7.1% [n = 1] vs 1.4% [n = 1], p = 0.200) and intraabdominal infections (7.1% [n = 1] vs 2.9% [n = 2], p = 0.430) were similar for IBD vs IBD-free, respectively. IBD did not affect OS (HR [95% CI]: 1.1 [0.4, 2.9]) or PFS (HR [95% CI]: 1.2 [0.4, 3.9]).

Conclusion

IBD is associated with a higher rate of gastrointestinal complications after CRS/HIPEC for appendix/colon cancer; however, it does not affect OS or PFS.

背景炎症性肠病(IBD)可能会影响针对阑尾/结肠癌腹膜转移(PM)的细胞切除手术联合腹腔热化疗(CRS/HIPEC)的疗效。我们对并发 IBD 患者的 CRS/HIPEC 结果进行了评估。方法使用前瞻性机构 CRS/HIPEC 数据库(1998-2023 年)进行了一项匹配队列研究,纳入了阑尾/结肠癌 PM 患者。我们将 IBD 患者与无 IBD 对照组按 1:5 的比例进行了匹配,对性别、年龄和腹膜癌指数 (PCI) 进行了最近邻倾向评分,并对既往 CRS/HIPEC 和原发肿瘤进行了精确匹配。比较了围手术期变量,包括 Clavien-Dindo 90 天并发症。结果 在 605 例阑尾/结肠癌 CRS/HIPEC 中,14 例(2.3%)同时患有克罗恩病(6 例)或溃疡性结肠炎(8 例)。70 名无 IBD 的对照组进行了配对。9名(64.7%)IBD患者有阑尾原发癌。10例(71.4%)IBD患者和57例(81.4%)无IBD患者实现了完全细胞减灭术(CC-0/1)(P = 0.468)。IBD 与无 IBD 患者相比,III/IV 级并发症的发生率更高(35.7% [n = 5] vs 15.7% [n = 11],p = 0.082),严重恶心/呕吐(35.7% vs 4.3%,p < 0.001)和腹泻(28.6% vs 8.6%,p = 0.035)的发生率也更高。IBD患者与无IBD患者的吻合口漏(7.1% [n = 1] vs 1.4% [n = 1],p = 0.200)和腹腔内感染(7.1% [n = 1] vs 2.9% [n = 2],p = 0.430)发生率相似。IBD不影响OS(HR [95% CI]:1.1 [0.4, 2.9])或PFS(HR [95% CI]:1.2 [0.4, 3.9])。
{"title":"Surgical management of peritoneal metastases from appendix and colon cancer in patients with inflammatory bowel disease","authors":"Vladislav Kovalik,&nbsp;Mary Caitlin King,&nbsp;Sergei Iugai,&nbsp;Luis Felipe Falla-Zuniga,&nbsp;Carol Nieroda,&nbsp;Armando Sardi,&nbsp;Vadim Gushchin","doi":"10.1016/j.soi.2024.100092","DOIUrl":"10.1016/j.soi.2024.100092","url":null,"abstract":"<div><h3>Background</h3><p>Inflammatory bowel disease (IBD) may compromise outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal metastases (PM) from appendix/colon cancer. We evaluated CRS/HIPEC outcomes in patients with concurrent IBD.</p></div><div><h3>Methods</h3><p>A matched cohort study using a prospective institutional CRS/HIPEC database (1998–2023) included appendix/colon cancer patients with PM. We matched IBD patients to IBD-free controls in a 1:5 ratio with nearest-neighbor propensity score for sex, age, and peritoneal cancer index (PCI), and exact matching for prior CRS/HIPEC and primary tumor. Perioperative variables, including Clavien-Dindo 90-day complications, were compared. Kaplan-Meier overall (OS) and progression-free survival (PFS) were compared using stratified Cox regression.</p></div><div><h3>Results</h3><p>Of 605 CRS/HIPECs for appendix/colon cancer, 14 (2.3%) had concurrent Crohn’s disease (n = 6) or ulcerative colitis (n = 8). Seventy IBD-free controls were matched. Nine (64.7%) IBD patients had an appendix primary. Complete cytoreduction (CC-0/1) was achieved in 10 (71.4%) IBD and 57 (81.4%) IBD-free patients (p = 0.468). IBD vs IBD-free patients tended to have more grade-III/IV complications (35.7% [n = 5] vs 15.7% [n = 11], p = 0.082) and had a higher rate of severe nausea/vomiting (35.7% vs 4.3 %, p &lt; 0.001) and diarrhea (28.6% vs 8.6%, p = 0.035). Rates of anastomotic leak (7.1% [n = 1] vs 1.4% [n = 1], p = 0.200) and intraabdominal infections (7.1% [n = 1] vs 2.9% [n = 2], p = 0.430) were similar for IBD vs IBD-free, respectively. IBD did not affect OS (HR [95% CI]: 1.1 [0.4, 2.9]) or PFS (HR [95% CI]: 1.2 [0.4, 3.9]).</p></div><div><h3>Conclusion</h3><p>IBD is associated with a higher rate of gastrointestinal complications after CRS/HIPEC for appendix/colon cancer; however, it does not affect OS or PFS.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100092"},"PeriodicalIF":0.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001014/pdfft?md5=5d30dbe9e2d5373a8c1c9cac5f48d2f9&pid=1-s2.0-S2950247024001014-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant breast radiation therapy practice patterns in the United States from 2012–2017 2012-2017 年美国乳腺辅助放射治疗的实践模式
Pub Date : 2024-08-25 DOI: 10.1016/j.soi.2024.100093
Jaclyn A. Gellings , Chandler S. Cortina , Julie Kijak , Julie Bradley , Mohammed Aldakkak , Carmen Bergom , Amanda L. Kong

Factors associated with selection of proton therapy (PT) or intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation in breast cancer were evaluated. As PT usage increases, data on local control, survival, long-term sequelae, and patient-reported outcomes of PT vs photon therapy are important to guide optimal application of radiation techniques.

研究评估了乳腺癌患者选择质子治疗(PT)或调强放射治疗(IMRT)与三维适形放射治疗的相关因素。随着质子疗法使用率的增加,有关质子疗法与光子疗法的局部控制、生存率、长期后遗症和患者报告结果的数据对于指导放射技术的最佳应用非常重要。
{"title":"Adjuvant breast radiation therapy practice patterns in the United States from 2012–2017","authors":"Jaclyn A. Gellings ,&nbsp;Chandler S. Cortina ,&nbsp;Julie Kijak ,&nbsp;Julie Bradley ,&nbsp;Mohammed Aldakkak ,&nbsp;Carmen Bergom ,&nbsp;Amanda L. Kong","doi":"10.1016/j.soi.2024.100093","DOIUrl":"10.1016/j.soi.2024.100093","url":null,"abstract":"<div><p>Factors associated with selection of proton therapy (PT) or intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation in breast cancer were evaluated. As PT usage increases, data on local control, survival, long-term sequelae, and patient-reported outcomes of PT vs photon therapy are important to guide optimal application of radiation techniques.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100093"},"PeriodicalIF":0.0,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001026/pdfft?md5=1aea204f46e9b6050913330630a9d023&pid=1-s2.0-S2950247024001026-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DNA mismatch repair deficiency as a biomarker in sarcoma 作为肉瘤生物标志物的 DNA 错配修复缺陷
Pub Date : 2024-08-22 DOI: 10.1016/j.soi.2024.100091
Ryan A. Denu , Christopher D. Quintana-Perez , Sintawat Wangsiricharoen , Davis R. Ingram , Khalida M. Wani , Alexander J. Lazar , Ravin Ratan , Christina L. Roland , Y. Nancy You

Purpose

Lynch syndrome (LS) is a cancer predisposition syndrome caused by a germline loss-of-function mutation in a mismatch repair (MMR) gene. While sarcomas are not classically considered LS cancers, we investigated the MMR status and clinical features of sarcomas in LS patients to help inform optimal treatment strategies.

Methods

A prospectively maintained institutional clinical cancer genetics database was queried for LS patients (defined by pathogenic germline mutation in a MMR gene) with a documented diagnosis of sarcoma between 1998–2022. Tumor MMR status was determined by immunohistochemistry (IHC) for MMR proteins and secondarily by PCR assay if IHC was normal or intact.

Results

Among the 30 LS patients with sarcoma, germline mutations were most common in MSH2 (50 %). The most common sarcoma subtypes were undifferentiated pleomorphic sarcoma (40 %) and leiomyosarcoma (27 %). Median age at diagnosis was 49.2 years (interquartile range 40.4–62.4). 90 % presented with localized disease, and 10 % presented with synchronous metastatic disease. Among 10 patients with tissue available for biomarker determination, dMMR was confirmed in 4 (40 %), while the remaining (60 %) were pMMR. Three patients received immunotherapy. Two of these had confirmed dMMR tumor status: one demonstrated a sustained complete response on pembrolizumab monotherapy for 44 months; the other had a partial response on ipilimumab and nivolumab for 31 months but died from an unrelated cause. In the entire cohort of 30 patients at a median follow-up time of 68.2 months since sarcoma diagnosis (interquartile range 29.0–151.5 months), median overall survival and progression-free survival have not been reached.

Conclusion

While rare, sarcoma can be encountered in patients with LS, particularly those with germline MSH2 mutation. LS-associated sarcomas occur significantly earlier, carry a favorable outcome, and demonstrate the potential for durable response with immunotherapy.

目的 林奇综合征(LS)是一种癌症易感综合征,由错配修复(MMR)基因的种系功能缺失突变引起。虽然肉瘤不属于LS癌症,但我们对LS患者的MMR状态和肉瘤的临床特征进行了调查,以便为最佳治疗策略提供参考。方法在1998年至2022年期间,我们查询了一个前瞻性维护的机构临床癌症遗传学数据库,其中记录了诊断为肉瘤的LS患者(定义为MMR基因的致病性种系突变)。肿瘤 MMR 状态通过 MMR 蛋白的免疫组织化学(IHC)来确定,如果 IHC 正常或完整,则通过 PCR 检测来确定。结果在 30 例 LS 肉瘤患者中,MSH2 的种系突变最为常见(50%)。最常见的肉瘤亚型是未分化多形性肉瘤(40%)和白肌肉瘤(27%)。确诊时的中位年龄为 49.2 岁(四分位距为 40.4-62.4 岁)。90%的患者表现为局部疾病,10%的患者表现为同步转移性疾病。10 名患者中,有 4 人(40%)的组织可用于生物标记物测定,证实为 dMMR,其余(60%)为 pMMR。三名患者接受了免疫疗法。其中两名患者的肿瘤状态被证实为dMMR:一名患者在接受pembrolizumab单药治疗44个月后出现持续完全应答;另一名患者在接受ipilimumab和nivolumab治疗31个月后出现部分应答,但死于与此无关的原因。在整个队列的30名患者中,自肉瘤确诊以来的中位随访时间为68.2个月(四分位间范围为29.0-151.5个月),尚未达到中位总生存期和无进展生存期。LS相关肉瘤的发病率明显较高,预后良好,并显示出免疫疗法可产生持久反应的潜力。
{"title":"DNA mismatch repair deficiency as a biomarker in sarcoma","authors":"Ryan A. Denu ,&nbsp;Christopher D. Quintana-Perez ,&nbsp;Sintawat Wangsiricharoen ,&nbsp;Davis R. Ingram ,&nbsp;Khalida M. Wani ,&nbsp;Alexander J. Lazar ,&nbsp;Ravin Ratan ,&nbsp;Christina L. Roland ,&nbsp;Y. Nancy You","doi":"10.1016/j.soi.2024.100091","DOIUrl":"10.1016/j.soi.2024.100091","url":null,"abstract":"<div><h3>Purpose</h3><p>Lynch syndrome (LS) is a cancer predisposition syndrome caused by a germline loss-of-function mutation in a mismatch repair (MMR) gene. While sarcomas are not classically considered LS cancers, we investigated the MMR status and clinical features of sarcomas in LS patients to help inform optimal treatment strategies.</p></div><div><h3>Methods</h3><p>A prospectively maintained institutional clinical cancer genetics database was queried for LS patients (defined by pathogenic germline mutation in a MMR gene) with a documented diagnosis of sarcoma between 1998–2022. Tumor MMR status was determined by immunohistochemistry (IHC) for MMR proteins and secondarily by PCR assay if IHC was normal or intact.</p></div><div><h3>Results</h3><p>Among the 30 LS patients with sarcoma, germline mutations were most common in <em>MSH2</em> (50 %). The most common sarcoma subtypes were undifferentiated pleomorphic sarcoma (40 %) and leiomyosarcoma (27 %). Median age at diagnosis was 49.2 years (interquartile range 40.4–62.4). 90 % presented with localized disease, and 10 % presented with synchronous metastatic disease. Among 10 patients with tissue available for biomarker determination, dMMR was confirmed in 4 (40 %), while the remaining (60 %) were pMMR. Three patients received immunotherapy. Two of these had confirmed dMMR tumor status: one demonstrated a sustained complete response on pembrolizumab monotherapy for 44 months; the other had a partial response on ipilimumab and nivolumab for 31 months but died from an unrelated cause. In the entire cohort of 30 patients at a median follow-up time of 68.2 months since sarcoma diagnosis (interquartile range 29.0–151.5 months), median overall survival and progression-free survival have not been reached.</p></div><div><h3>Conclusion</h3><p>While rare, sarcoma can be encountered in patients with LS, particularly those with germline <em>MSH2</em> mutation. LS-associated sarcomas occur significantly earlier, carry a favorable outcome, and demonstrate the potential for durable response with immunotherapy.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100091"},"PeriodicalIF":0.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024001002/pdfft?md5=ab6d50594cef0801f725d56e6a363e9b&pid=1-s2.0-S2950247024001002-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laparoscopic versus robotic pancreaticoduodenectomy: A NSQIP analysis comparing trends in patient selection and outcomes over 5-years 腹腔镜与机器人胰十二指肠切除术:一项NSQIP分析比较了5年来在患者选择和疗效方面的趋势
Pub Date : 2024-08-12 DOI: 10.1016/j.soi.2024.100090
Kevin Verhoeff , Juan Glinka , Douglas Quan , Ephraim S. Tang , Anton Skaro

Background

Comparison of laparoscopic (LPD) and robotic (RPD) pancreaticoduodenectomy over time remains limited. This study aims to compare LPD and RPD and to describe the demographics and outcomes of patients undergoing MIS pancreaticoduodenectomy over 5-years.

Methods

The ACS-NSQIP (2016–2021) database was used to evaluate patients undergoing MIS pancreaticoduodenectomy comparing LPD versus RPD. Patient characteristics, and outcomes were compared and multivariable modelling evaluated factors associated with serious complications, and mortality. MIS approach, demographics, and outcomes were assessed yearly to evaluate trends over time.

Results

We evaluated 1707 patients with 1148 (67.3 %) receiving RPD. Cohorts were similar with regards to demographic factors, however, patients undergoing RPD were less likely to be partially dependent (0.5 % vs. 1.6 %; p = 0.024), and more likely to receive neoadjuvant therapy (26.8 % vs. 21.7 %; p = 0.023).

Bivariate analysis demonstrated similar operative duration (444.1 vs 429.9 min; p = 0.074), but shorter LOS (8.5 vs. 9.8 days; p < 0.001), and higher readmission rate (21.5 % vs. 15.6 %; p = 0.004) with RPD. Additionally, RPD required transfusion less often (10.5 % vs. 21.7 %; p < 0.001). Multivariable analysis demonstrated that LPD was not independently associated with serious complications (OR 1.27 p = 0.094) or mortality (OR 0.82, p = 0.611).

Analysis of trends from 2016 to 2021 demonstrated similar patient selection and outcomes but a significant increase in MIS pancreaticoduodenectomy (281 to 428), primarily driven by an increase in RPD.

Conclusions

Comparing LPD and RPD there is no difference in serious complications or mortality. MIS pancreaticoduodenectomy has increased over the last 5 years but volumes remain small with similar demographics and outcomes over time.

背景腹腔镜(LPD)和机器人(RPD)胰十二指肠切除术的长期比较仍然有限。本研究旨在对LPD和RPD进行比较,并描述5年内接受MIS胰十二指肠切除术的患者的人口统计学特征和预后。比较了患者特征和预后,并通过多变量模型评估了与严重并发症和死亡率相关的因素。每年对 MIS 方法、人口统计学和结果进行评估,以评估随时间变化的趋势。 结果我们评估了 1707 例患者,其中 1148 例(67.3%)接受了 RPD。人群的人口统计学因素相似,但接受RPD的患者部分依赖的可能性较低(0.5 % vs. 1.6 %; p = 0.024),接受新辅助治疗的可能性较高(26.8 % vs. 21.双变量分析显示,RPD 的手术时间相似(444.1 分钟 vs 429.9 分钟;p = 0.074),但 LOS 更短(8.5 天 vs 9.8 天;p < 0.001),再入院率更高(21.5% vs 15.6%;p = 0.004)。此外,RPD 需要输血的次数较少(10.5% 对 21.7%;p = 0.001)。多变量分析表明,LPD与严重并发症(OR 1.27,p = 0.094)或死亡率(OR 0.82,p = 0.611)无独立关联。对2016年至2021年的趋势分析表明,患者选择和结果相似,但MIS胰十二指肠切除术显著增加(从281例增至428例),主要是由于RPD的增加。MIS胰十二指肠切除术在过去5年中有所增加,但手术量仍然很小,人口统计学和手术结果与过去相似。
{"title":"Laparoscopic versus robotic pancreaticoduodenectomy: A NSQIP analysis comparing trends in patient selection and outcomes over 5-years","authors":"Kevin Verhoeff ,&nbsp;Juan Glinka ,&nbsp;Douglas Quan ,&nbsp;Ephraim S. Tang ,&nbsp;Anton Skaro","doi":"10.1016/j.soi.2024.100090","DOIUrl":"10.1016/j.soi.2024.100090","url":null,"abstract":"<div><h3>Background</h3><p>Comparison of laparoscopic (LPD) and robotic (RPD) pancreaticoduodenectomy over time remains limited. This study aims to compare LPD and RPD and to describe the demographics and outcomes of patients undergoing MIS pancreaticoduodenectomy over 5-years.</p></div><div><h3>Methods</h3><p>The ACS-NSQIP (2016–2021) database was used to evaluate patients undergoing MIS pancreaticoduodenectomy comparing LPD versus RPD. Patient characteristics, and outcomes were compared and multivariable modelling evaluated factors associated with serious complications, and mortality. MIS approach, demographics, and outcomes were assessed yearly to evaluate trends over time.</p></div><div><h3>Results</h3><p>We evaluated 1707 patients with 1148 (67.3 %) receiving RPD. Cohorts were similar with regards to demographic factors, however, patients undergoing RPD were less likely to be partially dependent (0.5 % vs. 1.6 %; p = 0.024), and more likely to receive neoadjuvant therapy (26.8 % vs. 21.7 %; p = 0.023).</p><p>Bivariate analysis demonstrated similar operative duration (444.1 vs 429.9 min; p = 0.074), but shorter LOS (8.5 vs. 9.8 days; p &lt; 0.001), and higher readmission rate (21.5 % vs. 15.6 %; p = 0.004) with RPD. Additionally, RPD required transfusion less often (10.5 % vs. 21.7 %; p &lt; 0.001). Multivariable analysis demonstrated that LPD was not independently associated with serious complications (OR 1.27 p = 0.094) or mortality (OR 0.82, p = 0.611).</p><p>Analysis of trends from 2016 to 2021 demonstrated similar patient selection and outcomes but a significant increase in MIS pancreaticoduodenectomy (281 to 428), primarily driven by an increase in RPD.</p></div><div><h3>Conclusions</h3><p>Comparing LPD and RPD there is no difference in serious complications or mortality. MIS pancreaticoduodenectomy has increased over the last 5 years but volumes remain small with similar demographics and outcomes over time.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100090"},"PeriodicalIF":0.0,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000999/pdfft?md5=c3a7ec9b70f7781d545673aca06a054e&pid=1-s2.0-S2950247024000999-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nerve graft reconstruction of irradiated oncologic segmental nerve defects in the extremities: A case series 四肢放射肿瘤节段性神经缺损的神经移植重建术:病例系列
Pub Date : 2024-08-10 DOI: 10.1016/j.soi.2024.100089
Yannick Albert J. Hoftiezer , Floris V. Raasveld , Joseph O. Werenski , H.W.B. Schreuder Bart , Dietmar J.O. Ulrich , E.P.A. van der Heijden Brigitte , Kyle R. Eberlin , Santiago A. Lozano-Calderón

Background

Neurovascular involvement of extremity neoplasms is historically considered a contraindication for limb-salvage surgery, due to concerns of limb dysfunction secondary to motor and/or sensory loss. Theoretically, large nerve defects may be amenable to reconstruction using grafts, but the outcomes of these techniques in irradiated oncologic patients remain unclear.

Methods

This study investigates reconstruction of oncologic nerve defects in the extremities in patients who underwent (neo)adjuvant radiotherapy. A retrospective series of ten patients with extremity sarcoma is provided, with six lower extremity and four upper extremity cases. Reconstruction consisted of nerve grafting with or without the addition of tendon transfers. The mean duration of clinical follow-up was 42.5 months.

Results

Nerve graft reconstruction led to recovery of motor or sensory function in eight out of ten patients thereby allowing functional limb preservation, with none of the patients developing significant neuropathic pain, a common complication in oncologic resections of the extremities with nerve involvement or following amputation. Thus, radiotherapy does not seem to completely preclude successful graft reconstruction of large oncologic extremity nerve defects.

Conclusions

Although the oncologic disease itself is associated with significant mortality, the results of the nerve reconstruction were encouraging despite the concomitant use of radiation. Based on the available data and literature, we recommend to at least discuss the option of graft-based nerve reconstruction with affected patients if relevant characteristics such as patient comorbidities and the viability of recipient muscle are favorable.

Synopsis

In this study, the results of nerve graft reconstruction of large sarcoma-related nerve defects were evaluated. This type of reconstruction seems feasible even in irradiated limbs, thereby aiding in functional limb preservation.

背景四肢肿瘤的神经血管受累历来被认为是肢体修复手术的禁忌症,因为人们担心运动和/或感觉缺失会继发肢体功能障碍。从理论上讲,大面积神经缺损可以使用移植物进行重建,但这些技术在接受过放射治疗的肿瘤患者中的效果仍不明确。本研究提供了 10 例四肢肉瘤患者的回顾性系列研究,其中 6 例为下肢,4 例为上肢。重建包括神经移植和肌腱转移。结果神经移植重建术使 10 例患者中的 8 例恢复了运动或感觉功能,从而保留了肢体功能,没有一例患者出现明显的神经痛,而神经痛是四肢肿瘤切除术中神经受累或截肢后常见的并发症。因此,放疗似乎并不完全排除成功移植重建大面积肿瘤性四肢神经缺损的可能性。结论尽管肿瘤疾病本身与高死亡率有关,但尽管同时使用了放射线,神经重建的结果还是令人鼓舞的。根据现有的数据和文献,我们建议,如果患者的合并症和受体肌肉的存活能力等相关特征良好,至少应与患者讨论移植神经重建的选择。这种重建方式即使在辐照肢体上也是可行的,从而有助于保留肢体功能。
{"title":"Nerve graft reconstruction of irradiated oncologic segmental nerve defects in the extremities: A case series","authors":"Yannick Albert J. Hoftiezer ,&nbsp;Floris V. Raasveld ,&nbsp;Joseph O. Werenski ,&nbsp;H.W.B. Schreuder Bart ,&nbsp;Dietmar J.O. Ulrich ,&nbsp;E.P.A. van der Heijden Brigitte ,&nbsp;Kyle R. Eberlin ,&nbsp;Santiago A. Lozano-Calderón","doi":"10.1016/j.soi.2024.100089","DOIUrl":"10.1016/j.soi.2024.100089","url":null,"abstract":"<div><h3>Background</h3><p>Neurovascular involvement of extremity neoplasms is historically considered a contraindication for limb-salvage surgery, due to concerns of limb dysfunction secondary to motor and/or sensory loss. Theoretically, large nerve defects may be amenable to reconstruction using grafts, but the outcomes of these techniques in irradiated oncologic patients remain unclear.</p></div><div><h3>Methods</h3><p>This study investigates reconstruction of oncologic nerve defects in the extremities in patients who underwent (neo)adjuvant radiotherapy. A retrospective series of ten patients with extremity sarcoma is provided, with six lower extremity and four upper extremity cases. Reconstruction consisted of nerve grafting with or without the addition of tendon transfers. The mean duration of clinical follow-up was 42.5 months.</p></div><div><h3>Results</h3><p>Nerve graft reconstruction led to recovery of motor or sensory function in eight out of ten patients thereby allowing functional limb preservation, with none of the patients developing significant neuropathic pain, a common complication in oncologic resections of the extremities with nerve involvement or following amputation. Thus, radiotherapy does not seem to completely preclude successful graft reconstruction of large oncologic extremity nerve defects.</p></div><div><h3>Conclusions</h3><p>Although the oncologic disease itself is associated with significant mortality, the results of the nerve reconstruction were encouraging despite the concomitant use of radiation. Based on the available data and literature, we recommend to at least discuss the option of graft-based nerve reconstruction with affected patients if relevant characteristics such as patient comorbidities and the viability of recipient muscle are favorable.</p></div><div><h3>Synopsis</h3><p>In this study, the results of nerve graft reconstruction of large sarcoma-related nerve defects were evaluated. This type of reconstruction seems feasible even in irradiated limbs, thereby aiding in functional limb preservation.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100089"},"PeriodicalIF":0.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000987/pdfft?md5=30608987aa8614b7fd47e7e85eb7641d&pid=1-s2.0-S2950247024000987-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141978296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolution of breast ultrasound in surgical practice: Current applications, missed opportunities, and future directions 乳腺超声在外科实践中的发展:当前应用、错失良机和未来方向
Pub Date : 2024-08-07 DOI: 10.1016/j.soi.2024.100084
Amanda N. Labora, Nimmi S. Kapoor

Ultrasound provides essential diagnostic and therapeutic applications in almost every medical and surgical field. In breast surgery, the importance of ultrasound cannot be overstated as it plays a critical role in both radiographic and tissue diagnosis, and can be used to guide surgical resection. Newer, cheaper, and more portable ultrasounds facilitate its use in the clinic and the operating room, making it a cost-effective, patient-centered tool in the management of benign and malignant breast conditions. This paper provides an overview of the evolution of breast ultrasound in surgical practice, its potential underuse in surgery, and explores emerging applications in breast surgery. Lastly, we identify opportunities for improvement in education, training, and access to ultrasound to overcome some of the barriers to ultrasound use by surgeons.

超声波在几乎所有医疗和外科领域都有重要的诊断和治疗应用。在乳腺外科手术中,超声波的重要性无论如何强调都不为过,因为它在影像学和组织诊断中发挥着关键作用,并可用于指导手术切除。更新、更便宜、更便携的超声波便于在临床和手术室中使用,使其成为治疗良性和恶性乳腺疾病的一种具有成本效益、以病人为中心的工具。本文概述了乳腺超声在外科实践中的演变、其在外科中可能存在的使用不足,并探讨了乳腺外科中的新兴应用。最后,我们指出了在教育、培训和获取超声方面的改进机会,以克服外科医生使用超声的一些障碍。
{"title":"The evolution of breast ultrasound in surgical practice: Current applications, missed opportunities, and future directions","authors":"Amanda N. Labora,&nbsp;Nimmi S. Kapoor","doi":"10.1016/j.soi.2024.100084","DOIUrl":"10.1016/j.soi.2024.100084","url":null,"abstract":"<div><p>Ultrasound provides essential diagnostic and therapeutic applications in almost every medical and surgical field. In breast surgery, the importance of ultrasound cannot be overstated as it plays a critical role in both radiographic and tissue diagnosis, and can be used to guide surgical resection. Newer, cheaper, and more portable ultrasounds facilitate its use in the clinic and the operating room, making it a cost-effective, patient-centered tool in the management of benign and malignant breast conditions. This paper provides an overview of the evolution of breast ultrasound in surgical practice, its potential underuse in surgery, and explores emerging applications in breast surgery. Lastly, we identify opportunities for improvement in education, training, and access to ultrasound to overcome some of the barriers to ultrasound use by surgeons.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100084"},"PeriodicalIF":0.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000938/pdfft?md5=cea31fbc3328ea308b3dae0a09ab9553&pid=1-s2.0-S2950247024000938-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141952898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is it time to de-escalate axillary surgery in patients with ductal carcinoma in-situ undergoing mastectomy? 对接受乳房切除术的原位导管癌患者来说,现在是否应该停止腋窝手术?
Pub Date : 2024-08-07 DOI: 10.1016/j.soi.2024.100085
Jamila Alazhri , Eman Hamza , Fozan Aldulaijan , Sarah Alajmi , Elinor Doherty , Lebogangk Tafangombe , Eithne Downey , Aishling Hegarty , Abeeda Butt , Arnold Hill

Introduction

Axillary surgery has been de-escalated in invasive breast carcinoma and may be omitted in certain age groups. Up to 10–20 % of patients with ductal carcinoma in-situ (DCIS) will have an element of invasion. Therefore, SLNB is indicated to rule out nodal metastasis. Our purpose was to identify the rate and possible risk factors for lymph node metastasis in DCIS, and to measure oncological outcome of positive SLNB in this group.

Methods

A retrospective analysis was performed on 113 female patients with DCIS, who underwent mastectomy and SLNB. Their clinical and radiological features, as well as pre and post-operative histopathological characteristics were evaluated and data was reported over an average follow up period of 48 months.

Result

DCIS was upgraded to invasive cancer in 11 patients out of 113 (9.7 %). Five patients had positive SLNB (4.4 %), one micro-metastasis (0.8 %) and four macro-metastasis (3.5 %) All the five underwent axillary lymph node dissection (ALND) and all additional nodes retrieved were negative. High nuclear grade, Her2 neu overexpression, and palpable mass showed higher odds of association with metastasis to sentinel nodes. However, due to the low event rate, the association did not reach statistical significance. Seven patients (6.2 %) developed lymphedema, 4 of which after SLNB only. No regional recurrence was reported among our study sample.

Conclusion

This study confirms the very low rate of positive SLNB in patients with DCIS. It is time to de-escalate axillary surgery for patients with DCIS undergoing mastectomy and consider delayed SLNB for high risk group of patients.

导言:对于浸润性乳腺癌,腋窝手术已被降级,某些年龄段的患者可以省略腋窝手术。多达 10-20% 的原位乳腺导管癌 (DCIS) 患者会有浸润因素。因此,SLNB 可用于排除结节转移。我们的目的是确定 DCIS 淋巴结转移的发生率和可能的风险因素,并衡量该群体中 SLNB 阳性的肿瘤治疗效果。方法对 113 名接受乳房切除术和 SLNB 的 DCIS 女性患者进行了回顾性分析。结果 113 例患者中有 11 例(9.7%)DCIS 升级为浸润癌。五名患者SLNB阳性(4.4%),一名微转移(0.8%),四名大转移(3.5%),所有五名患者均接受了腋窝淋巴结清扫(ALND),所有其他取回的淋巴结均为阴性。核分级高、Her2 neu过表达和可触及肿块与前哨结节转移相关的几率较高。然而,由于事件发生率较低,相关性未达到统计学意义。7名患者(6.2%)出现淋巴水肿,其中4人仅在SLNB后出现淋巴水肿。结论这项研究证实,DCIS 患者的 SLNB 阳性率非常低。现在是时候对接受乳房切除术的 DCIS 患者降低腋窝手术等级,并考虑对高风险人群进行延迟 SLNB 了。
{"title":"Is it time to de-escalate axillary surgery in patients with ductal carcinoma in-situ undergoing mastectomy?","authors":"Jamila Alazhri ,&nbsp;Eman Hamza ,&nbsp;Fozan Aldulaijan ,&nbsp;Sarah Alajmi ,&nbsp;Elinor Doherty ,&nbsp;Lebogangk Tafangombe ,&nbsp;Eithne Downey ,&nbsp;Aishling Hegarty ,&nbsp;Abeeda Butt ,&nbsp;Arnold Hill","doi":"10.1016/j.soi.2024.100085","DOIUrl":"10.1016/j.soi.2024.100085","url":null,"abstract":"<div><h3>Introduction</h3><p>Axillary surgery has been de-escalated in invasive breast carcinoma and may be omitted in certain age groups. Up to 10–20 % of patients with ductal carcinoma in-situ (DCIS) will have an element of invasion. Therefore, SLNB is indicated to rule out nodal metastasis. Our purpose was to identify the rate and possible risk factors for lymph node metastasis in DCIS, and to measure oncological outcome of positive SLNB in this group.</p></div><div><h3>Methods</h3><p>A retrospective analysis was performed on 113 female patients with DCIS, who underwent mastectomy and SLNB. Their clinical and radiological features, as well as pre and post-operative histopathological characteristics were evaluated and data was reported over an average follow up period of 48 months.</p></div><div><h3>Result</h3><p>DCIS was upgraded to invasive cancer in 11 patients out of 113 (9.7 %). Five patients had positive SLNB (4.4 %), one micro-metastasis (0.8 %) and four macro-metastasis (3.5 %) All the five underwent axillary lymph node dissection (ALND) and all additional nodes retrieved were negative. High nuclear grade, Her2 neu overexpression, and palpable mass showed higher odds of association with metastasis to sentinel nodes. However, due to the low event rate, the association did not reach statistical significance. Seven patients (6.2 %) developed lymphedema, 4 of which after SLNB only. No regional recurrence was reported among our study sample.</p></div><div><h3>Conclusion</h3><p>This study confirms the very low rate of positive SLNB in patients with DCIS. It is time to de-escalate axillary surgery for patients with DCIS undergoing mastectomy and consider delayed SLNB for high risk group of patients.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 3","pages":"Article 100085"},"PeriodicalIF":0.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S295024702400094X/pdfft?md5=3956d534d5a0d91ec22c3d83c1aa4ec5&pid=1-s2.0-S295024702400094X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141992773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Surgical Oncology Insight
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1